Frontage Acquires Majority Stake in Wuhan Heyan Biomedical, a CRO

Frontage  Shanghai , a division of US-China CRO Frontage Holdings, acquired a 70% stake in Wuhan Heyan Biomedical Technology, a discovery CRO. Heyan offers target-based in vitro pharmacodynamic screening and early pharmacological pharmacodynamic evaluation services for biologic drug discovery. Its technical services include screening of drug targets, customized biological assay development and detection services. Frontage, which is majority owned by Hangzhou 's TigerMed, offers drug evaluation, product development/CMC and clinical services. More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.